|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||215.78 / 374.99|
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
A bear market, if it gets us all to slow down, may be necessary to slow the coronavirus' spread -- but this doesn't mean I'm giving up. To the contrary.
Let's check out the charts of SGMO and come up with a trading strategy.
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
It's no secret that the Fed would like to get out of the short-term repo business.
The Medical Technology Stock Letter's top pick rose 357% in 2019.
Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.
A lot of the names that fell hard after the Clinton impeachment have been record earners since then.
We're seeing lots of companies snapping up their peers, and the market is applauding.
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.
Breaking down an approach to the long side of this biotech stock.
These stocks are priced for total imperfection. That's just what you want.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
This looks like a normal pause within an uptrend.
BIIB also reported third quarter results Tuesday that easily beat the consensus both on the top and the bottom line.
There is a chance that Presidents Trump and Xi sign something when they meet up at the APEC summit this November in Santiago, Chile.
Dozens of beaten-up stocks could see tax-loss selling into the end of the year; here's a preview of some that could make up the next Tax Loss Selling Portfolio.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.